The constitutive activation of HER2 (erbB2, neu) based on overexpression and/or mutation has been observed in various cancers, including ovarian carcinoma, and has been linked to disease progression, resistance to treatment and poor prognosis [2,3,4]. The gene discussed is ERBB2; the disease is ovarian carcinoma.